Company Overview

Micro Imaging Technology, Inc. (OTC: MMTC) was a U.S.-based technology and life sciences company focused on the development of rapid microbial detection systems for use in food safety, healthcare, pharmaceutical, and industrial testing environments. According to historical public disclosures and filings, the company’s core objective was to commercialize automated systems capable of identifying harmful bacteria and pathogens more quickly than traditional laboratory culturing methods. The company operated within the broader biotechnology, diagnostic instrumentation, and food safety testing industries.

The company’s primary business activity centered on proprietary microbial identification technology intended to reduce testing times for food processors, laboratories, and healthcare-related customers. Public filings indicate that MMTC positioned itself around speed, automation, and lower-cost pathogen detection compared with conventional methods. Historical records suggest the company underwent multiple stages of development and commercialization efforts, though available public information indicates limited commercial scale and inconsistent revenue generation. Data regarding later-stage operational progress and current business activity is inconclusive based on available public sources.

Business Operations

Historically, Micro Imaging Technology generated little recurring commercial revenue and was primarily engaged in research, development, intellectual property development, and efforts to commercialize its microbial detection platform. Its principal operating focus was the development of automated identification instruments capable of detecting microorganisms in samples used across food production and laboratory settings. Public disclosures referenced the company’s proprietary microbial identification technology and related software systems as its principal assets.

The company’s operations appeared to be concentrated primarily within the United States, with limited evidence of substantial international operating infrastructure. Historical filings and OTC market disclosures referenced relationships with laboratories, research institutions, and potential commercialization partners, although publicly verified information regarding large-scale joint ventures or material operating subsidiaries remains limited. Data concerning active subsidiaries, large strategic partnerships, or significant international business operations is inconclusive based on available public sources.

Strategic Position & Investments

Micro Imaging Technology’s strategic direction historically focused on expanding the adoption of rapid pathogen detection technologies in industries where contamination monitoring and regulatory compliance are critical. Public company materials indicated that management viewed food safety testing as a primary commercial opportunity, particularly as global food producers faced increasing regulatory oversight and demand for faster microbial testing solutions. The company also referenced potential applications in pharmaceutical manufacturing and healthcare diagnostics.

Available public records do not indicate major acquisitions or a diversified investment portfolio comparable to larger biotechnology firms. The company’s strategy appeared centered on internal technology development rather than acquisition-driven expansion. Historical filings referenced ongoing investment into research and intellectual property protection related to automated microbial identification systems. However, evidence of large-scale commercialization, substantial institutional investment activity, or material expansion into adjacent technology sectors remains limited in publicly available records.

Geographic Footprint

Micro Imaging Technology was headquartered in the United States, and its business activities were primarily domestic based on historical regulatory filings and OTC disclosures. The company’s commercial focus targeted industries with global relevance, including food safety and laboratory diagnostics, but there is limited verified evidence of a broad international operating footprint or extensive foreign subsidiaries.

The company’s technology development and corporate activities were largely tied to the U.S. market, including outreach to food manufacturers, laboratories, and industrial testing organizations. Publicly available information does not clearly demonstrate significant operational infrastructure across Europe, Asia-Pacific, or Latin America. Data concerning international market penetration or sustained overseas revenue generation is inconclusive based on available public sources.

Leadership & Governance

Historical filings indicate that Micro Imaging Technology experienced multiple leadership and governance changes over time, which is not uncommon among developmental-stage public technology companies. Public disclosures and OTC filings identified executives and directors associated with commercialization, scientific development, and capital markets activities. However, current executive and governance information is limited and not consistently updated across publicly available records.

Key historical leadership figures identified in public disclosures include:

• Mitchell Felder – Former Chief Executive Officer
• Michael Kozole – Former Chief Financial Officer
• William P. Rhodes – Former Chairman and executive leadership figure

The company’s leadership strategy historically emphasized commercialization of proprietary microbial detection technology, intellectual property development, and securing industry adoption within food safety and laboratory testing markets. More recent governance information and executive status are inconclusive based on available public sources.